Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

By W. Colucci, U. Elkayam, D. Horton, W. Abraham, R. Bourge, Allen D. Johnson, L. Wagoner, M. Givertz, C. Liang, M. Neibaur and 2 more. New England Journal of Medicine, 2000

772 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Complementary and alternative medicine

View Paper: https://www.semanticscholar.org/paper/9e4c735d1e3416b2ea8dfb6968d5fd8f9990412b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. T. Horwich
3. J. Januzzi
4. C. Yancy
5. M. Drazner
6. Véronique L. Roger
7. M. Gheorghiade

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “LVEF to improve mortality and morbidity (344).”
• Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure (2005, methodology): “htm)26–29; (2) the sponsor of the drug (Scios Inc, Medical Affairs Department)30; (3) a literature search using PubMed (using the search criteria “nesiritide” limited to clinical trials on humans published in English through July 2004); and (4) a manual search of”
• Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. (2005, result): “The NSGET trial described mortality (over 21 days as it prespecified) as being similar between groups but this similarity was evident only after combining the results of this trial with a larger open-label study comparing nesiritide with dobutamine.(22) The VMAC trial reported mortality only at 7 da”